Cargando…

The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial

BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling and painful joints, eventually leading to joint destruction. There is still a lack of effective therapy to treat RA. The Juanbi pill is a Chinese medicine that has been widely used to treat active RA in C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiong, Wang, Yi-Ru, Jia, Qing-Yun, Liu, Li, Xu, Chong-Qing, Wang, Xiao-Yun, Yao, Min, Cui, Xue-Jun, Shi, Qi, Wang, Yong-Jun, Liang, Qian-Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859450/
https://www.ncbi.nlm.nih.gov/pubmed/29558967
http://dx.doi.org/10.1186/s13063-018-2555-1
_version_ 1783307824085860352
author Wang, Qiong
Wang, Yi-Ru
Jia, Qing-Yun
Liu, Li
Xu, Chong-Qing
Wang, Xiao-Yun
Yao, Min
Cui, Xue-Jun
Shi, Qi
Wang, Yong-Jun
Liang, Qian-Qian
author_facet Wang, Qiong
Wang, Yi-Ru
Jia, Qing-Yun
Liu, Li
Xu, Chong-Qing
Wang, Xiao-Yun
Yao, Min
Cui, Xue-Jun
Shi, Qi
Wang, Yong-Jun
Liang, Qian-Qian
author_sort Wang, Qiong
collection PubMed
description BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling and painful joints, eventually leading to joint destruction. There is still a lack of effective therapy to treat RA. The Juanbi pill is a Chinese medicine that has been widely used to treat active RA in China for hundreds of years, relieving pain and protecting the affected joints from malformation. However, there is no solid evidence to show the effect of the Juanbi pill on the management of active RA. METHODS/DESIGN: We will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to determine whether the traditional Chinese medicine Juanbi pill could relieve joint pain in RA and protect the joints. A total of 120 patients with active RA will be enrolled and treated with the Juanbi pill or a placebo for 3 months. The primary outcome measures are as follows: rate of in the American College of Rheumatology (ACR)50, change in the 28-joint Disease Activity Score (DAS28) from baseline at beginning of therapy to 3 months, and a change in the van der Heijde modified Sharp score measured from baseline to 12 months. The secondary outcome measures are as follows: rate of change in ACR20, ACR70, Health Assessment Questionnaire-Disability Index (HAQ-DI), and change in score in the Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, and the Athens Insomnia Scale (AIS) from baseline to 2-week, 1-month, 2-month, 3-month, 6-month, and 12-month follow up. In addition, the rate of change (score) in the ACR50 and DAS28 from the baseline to 2-week, 1-month, 2-month, 6-month, and 12-month follow up are also the secondary outcome measures. DISCUSSION: Although the Juanbi pill has been used in China for many years to treat RA, there is a lack of consensus about its effectiveness. This trial will provide convincing evidence about the effect of Juanbi pill on active RA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02885597. Registered on 30 August 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-018-2555-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5859450
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58594502018-03-20 The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial Wang, Qiong Wang, Yi-Ru Jia, Qing-Yun Liu, Li Xu, Chong-Qing Wang, Xiao-Yun Yao, Min Cui, Xue-Jun Shi, Qi Wang, Yong-Jun Liang, Qian-Qian Trials Study Protocol BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling and painful joints, eventually leading to joint destruction. There is still a lack of effective therapy to treat RA. The Juanbi pill is a Chinese medicine that has been widely used to treat active RA in China for hundreds of years, relieving pain and protecting the affected joints from malformation. However, there is no solid evidence to show the effect of the Juanbi pill on the management of active RA. METHODS/DESIGN: We will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to determine whether the traditional Chinese medicine Juanbi pill could relieve joint pain in RA and protect the joints. A total of 120 patients with active RA will be enrolled and treated with the Juanbi pill or a placebo for 3 months. The primary outcome measures are as follows: rate of in the American College of Rheumatology (ACR)50, change in the 28-joint Disease Activity Score (DAS28) from baseline at beginning of therapy to 3 months, and a change in the van der Heijde modified Sharp score measured from baseline to 12 months. The secondary outcome measures are as follows: rate of change in ACR20, ACR70, Health Assessment Questionnaire-Disability Index (HAQ-DI), and change in score in the Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, and the Athens Insomnia Scale (AIS) from baseline to 2-week, 1-month, 2-month, 3-month, 6-month, and 12-month follow up. In addition, the rate of change (score) in the ACR50 and DAS28 from the baseline to 2-week, 1-month, 2-month, 6-month, and 12-month follow up are also the secondary outcome measures. DISCUSSION: Although the Juanbi pill has been used in China for many years to treat RA, there is a lack of consensus about its effectiveness. This trial will provide convincing evidence about the effect of Juanbi pill on active RA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02885597. Registered on 30 August 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-018-2555-1) contains supplementary material, which is available to authorized users. BioMed Central 2018-03-20 /pmc/articles/PMC5859450/ /pubmed/29558967 http://dx.doi.org/10.1186/s13063-018-2555-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Wang, Qiong
Wang, Yi-Ru
Jia, Qing-Yun
Liu, Li
Xu, Chong-Qing
Wang, Xiao-Yun
Yao, Min
Cui, Xue-Jun
Shi, Qi
Wang, Yong-Jun
Liang, Qian-Qian
The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial
title The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial
title_full The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial
title_fullStr The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial
title_full_unstemmed The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial
title_short The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial
title_sort efficacy of the traditional chinese medicine juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859450/
https://www.ncbi.nlm.nih.gov/pubmed/29558967
http://dx.doi.org/10.1186/s13063-018-2555-1
work_keys_str_mv AT wangqiong theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT wangyiru theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT jiaqingyun theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT liuli theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT xuchongqing theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT wangxiaoyun theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT yaomin theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT cuixuejun theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT shiqi theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT wangyongjun theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT liangqianqian theefficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT wangqiong efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT wangyiru efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT jiaqingyun efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT liuli efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT xuchongqing efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT wangxiaoyun efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT yaomin efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT cuixuejun efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT shiqi efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT wangyongjun efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial
AT liangqianqian efficacyofthetraditionalchinesemedicinejuanbipillcombinedwithmethotrexateinactiverheumatoidarthritisstudyprotocolforarandomizedcontrolledtrial